Meysam Arbuzia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meysam Arbuzia has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hossein Mardanparvar
Department of Nursing, Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
3 shared publications - Jalal Rezaei
Department of Critical Care Nursing, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Sara Rasta
Department of Emergency Medicine, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ali Emadzadeh
Department of Internal Medicine, MMS.C., Islamic Azad University, Mashhad, Iran
1 shared publication - Amin Norouzbeygi
Department of Orthopedic and Trauma Surgery, School of Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
1 shared publication - Elham Ahmadipour
Independent Researcher, Private Clinic, Pezeshkan Street, Alvand Building, Shiraz, Iran
1 shared publication
Latest Publications
- Open Access
- 9 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12789
Air pollution and kidney disease; a comprehensive updated overview of recent evidence on functional and structural alterations
The association between air pollution and renal health has gained increasing attention in recent years, with evidence suggesting that prolonged exposure to air pollution poses significant threats to both renal function and structural integrity of kidneys, with both immediate and long-term consequences on kidney health. Studies have indicated that various air pollutants are linked to the onset and progression of chronic kidney disease (CKD) and other renal disorders. The evidence links short-term increases in pollutant concentrations to declines in glomerular filtration rates, while long-term exposure is associated with a heightened risk of CKD and structural damage to renal tissues. The mechanisms through which air pollution impacts renal health, systemic inflammation, oxidative stress, endothelial dysfunction, and direct nephrotoxicity highlight the urgent need for public health policies aimed at improving air quality and protecting kidney health. The evidence emphasizes air pollution as a critical environmental risk factor contributing to kidney diseases globally.
- 9 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12789
Open AccessAir pollution and kidney disease; a comprehensive updated overview of recent evidence on functional and structural alterations
The association between air pollution and renal health has gained increasing attention in recent years, with evidence suggesting that prolonged exposure to air pollution poses significant threats to both renal function and structural integrity of kidneys, with both immediate and long-term consequences on kidney health. Studies have indicated that various air pollutants are linked to the onset and progression of chronic kidney disease (CKD) and other renal disorders. The evidence links short-term increases in pollutant concentrations to declines in glomerular filtration rates, while long-term exposure is associated with a heightened risk of CKD and structural damage to renal tissues. The mechanisms through which air pollution impacts renal health, systemic inflammation, oxidative stress, endothelial dysfunction, and direct nephrotoxicity highlight the urgent need for public health policies aimed at improving air quality and protecting kidney health. The evidence emphasizes air pollution as a critical environmental risk factor contributing to kidney diseases globally.
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38256
Role of lipoprotein (a) in kidney diseases; a review of recent data
Lipoprotein (a) is a type of lipoprotein that consists of a cholesterol-rich low-density lipoprotein particle bound to a unique protein called apolipoprotein (a). A strengthened risk of vascular diseases, such as stroke and coronary artery disease is accompanied by elevated levels of this protein. However, recent research has also highlighted the potential role of lipoprotein (a) in kidney-related conditions. Lp (a) appears to play a significant role in kidney diseases. An increased risk of kidney disease development and progression, diabetic nephropathy and renal artery stenosis, and renal transplant dysfunction accompanies high plasma values of Lp (a).
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38256
Open AccessRole of lipoprotein (a) in kidney diseases; a review of recent data
Lipoprotein (a) is a type of lipoprotein that consists of a cholesterol-rich low-density lipoprotein particle bound to a unique protein called apolipoprotein (a). A strengthened risk of vascular diseases, such as stroke and coronary artery disease is accompanied by elevated levels of this protein. However, recent research has also highlighted the potential role of lipoprotein (a) in kidney-related conditions. Lp (a) appears to play a significant role in kidney diseases. An increased risk of kidney disease development and progression, diabetic nephropathy and renal artery stenosis, and renal transplant dysfunction accompanies high plasma values of Lp (a).
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Open AccessLimb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.